Sandoz

News

Sandoz encourages digital health innovation in second compet...

Sandoz has announced a second competition inviting entrepreneurs and innovators in digital health to submit ideas that could complement or even disrupt established approaches to access to h

Views & Analysis

Digital health round-up - government and Sandoz recognise tr...

Richard Staines presents his weekly round-up of the latest digital health headlines

News

Novartis sells parts of Sandoz for $1bn

After disappointing sales, Novartis trades in the Sandoz US dermatology business and generic oral solids portfolio to Aurobindo Pharma, in a deal worth nearly $1 billion.

News

Fourth Humira biosimilar set for EU approval

European regulators have backed a new Humira biosimilar for approval, setting up a four-way race for the blockbuster’s market share later this year between Amgen, Boehringer Ingelheim, Sams

News

Novartis and Pear to develop substance use digital therapeut...

Novartis is set to develop and commercialise a range of digital therapeutics for patients with substance and opioid use disorders as it expands its work with Pear Therapeutics through a dea

News

Biocon and Sandoz strike biosimilars partnership

Companies will develop and market several biosimilars

Sandoz encourages digital health innovation in second compet...

Digital health round-up - government and Sandoz recognise tr...

Novartis sells parts of Sandoz for $1bn

Fourth Humira biosimilar set for EU approval

Novartis and Pear to develop substance use digital therapeut...

Biocon and Sandoz strike biosimilars partnership

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Sandoz

Editor's Picks